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We report a 14-week post-marketing experience on 20 patients with multiple sclerosis (MS) who started prolonged-release (PR)
oral dalfampridine 10mg twice daily according to EuropeanMedicine Agency criteria. They underwent serial static posturography
assessments and the dizziness handicap inventory (DHI) to investigate whether PR dalfampridine could impact standing balance
and self-reported perception of balance. The incidence of accidental falls per person per month was also recorded throughout
the study. Eight (40%) patients, who had a relevant improvement in walking speed, were defined as treatment responders. They
showed a significant improvement of standing balance (with respect to pretreatment assessment) when contrasted with 12 (60%)
nonresponders (𝐹[4,15] = 3.959, 𝑃 = 0.027). No significant changes in DHI score, as well as in its functional, physical, and emotional
subscales, were found in both responders and nonresponders at the end of study (all P values are ≥0.2). Treatment response did
not affect the incidence of accidental falls. Future studies based on larger sample sizes, and with longer followup, are required to
confirm the beneficial effect of PR dalfampridine on standing balance.
1. Introduction
Reduced mobility, especially in walking, is probably the
impairment most frequently accounted as compromising
daily life activities of patients with multiple sclerosis (MS)
[1]. Lack of balance/coordination is reported by patients with
MS as one of the most common symptoms affecting mobility
(67%), together with leg weakness (81%), fatigue (73%), and
inability to walk long distances (69%) [2].
Lack of balance inMS remains largely incurable [3], since
pharmacological interventions to improve balance are often
inadequate, and some drugs broadly used in neurological
setting may even worsen gait and balance [4].
Prolonged-release (PR) oral dalfampridine, a voltage-
gated potassium channel blocker able to improve action pote-
ntial conduction in demyelinated axons, is the first drug
specifically licensed to improve walking in patients with MS
[5]. Several randomized clinical trials demonstrated that PR
dalfampridine can improve walking speed by approximately
25% in more than one-third of treated patients; moreover,
it can significantly improve perception of ambulatory per-
formance and lower extremity strength [6–9]. However, the
potential effectiveness of PR dalfampridine in ameliorating
balance is still debated, and an international, multicenter
clinical trial is ongoing to address this important issue
(NCT01597297) [10].
On the other hand, higher incidence of dizziness and
balance disorders has been described as a common adverse
event in PR dalfampridine-treated patients [8, 9].
In this study, we investigated whether PR dalfampridine
could impact standing balance, perception of balance, and
incidence of accidental falls in a cohort of patients with
MS.
2. Methods
2.1. Participants. A total of 20 consecutive patients with MS
according toMcDonald criteria [11], who started commercial
available PR dalfampridine tablets (10mg per os, twice daily)
according to European Medicine Agency criteria [12], were
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Figure 1: Study design and assessments. PR: prolonged release; 25-FWT: 25-timed foot walking test; DHI: dizziness handicap inventory.
recruited at MS Centre of S. Andrea Hospital, Sapienza
University, Rome, Italy. Eligibility criteria were age from 18 to
65 years; Expanded Disability Status Scale (EDSS) [13] score
from 4.0 to 7.0 (inclusive); ability to complete two trials of the
25-foot walking test (25-FWT) [14] in a maximum time of
180 seconds; ability to stand upright for at least 180 seconds
without any support. We excluded patients with history of
seizures, concomitant otological or vestibular diseases (non-
MS related), psychiatric comorbidities or severe cognitive
impairment, and cardiovascular and respiratory disorders.
An informed consent was obtained for each patient before
any study procedure. The local ethical committee board
provides exemption of approval for postapproval prospective
studies.
2.2. Study Design. This was a 14-week, independent, single-
centre, observational, postmarketing study.
Patients entered into the study at WK−4 visit. During
the initial 4-week screening period they neither did receive
PR dalfampridine nor changed their concomitant therapies.
Administration of PR dalfampridine started for all patients
at WK 0 visit, and response to treatment was assessed after
a 2-week run-in period, according to previously established
criteria based on 25-FWT [7]. A patient was defined as
a responder if he/she walked faster in 3 out of 4 trials
performed at the end of 2-week run-in period (WK+2
visit) versus the fastest performance of 5 weekly screening
evaluations. Treatment responders continued the treatment
with PR dalfampridine, while nonresponders discontinued it.
However, we continued to evaluate both groups every 4weeks
(WK+6 and WK+10 visits).
A +/− 3-day window was allowed for each visit, with
exception of WK 0 visit (when treatment response had to be
defined). Figure 1 shows the study design.
2.3. Study Assessments
Walking speed. The 25-FWT was performed at study entry
(WK−4) and every week up to WK 0 visit, for a total of 5
evaluations (screening period). Two 25-FWT trials, separated
by a 30-minute interval, were also performed at the end of the
first week and the second week of treatment (run-in period),
for a total of 4 evaluations.
Static Posturography. Patients were tested by means of
a laboratory-grade force platform (ProKin, Tecnobody,
Dalmine, Italy; 20Hz sampling rate, sensitivity 0.1∘) at each
visit by two trained physical therapists (DF and MRM),
unaware of clinical data and treatment response status. Static
posturography was performed according to a standardized
procedure as follows: each subject was asked to stand barefoot
on the ground, in upright static condition, double-leg stance
and with arms resting at their sides. The position of the feet
on the force-platform was standardized using a V-shaped
frame, keeping on a 3 cm distance between the two medial
malleoli and an extra rotation of 12∘ with respect to the
sagittal axis [15]. The sum of displacement of body’s centre of
pressure (COP) under open-eye condition in 30 seconds was
measured to estimate the extent of postural sway; wider sway
indicates worse standing balance. This parameter has been
reported to be highly reliable (95%) and also more accurate
than clinical scales in predicting accidental falls [16].
DHI. The questionnaire was administered to patients at
study entry (WK−4) and study termination (WK+10). The
DHI is a 25-item self-administered questionnaire rating the
self-perception of disability due to dizziness and imbalance
[17]. The total score ranges from 0 to 100, with higher
score indicating more severe disability. Subscores related to
physical, emotional, and functional domains can be also
calculated. DHI exhibited an excellent test-retest reliability
(90%), and a 50% sensitivity and 74% specificity in detecting
fallers among patients with MS were also reported when a
cut-off score of 59 was used [18].
Accidental Falls. At study entry (WK−4), and at WK+2 and
WK+6 visits, all patients received a diary to fill out and give
back the next visit, in order to estimate the month incidence
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Table 1: Patients’ characteristics at study entry.
Responders
𝑛 = 8
Nonresponders
𝑛 = 12
Pooled
𝑛 = 20
Gender: F :M 4 : 4 6 : 6 8 : 12
Age: years 45.2 (8.1) 44.6 (6.4) 44.8 (7.1)
MS duration: years 14.5 (7.9) 14.7 (6.9) 14.7 (7.2)
Disease course: RR : SP : PP 2 : 5 : 1 4 : 6 : 2 6 : 11 : 3
EDSS score: median [range] 5.0 [4.0–6.5] 5.0 [4.0–7.0] 5.0 [4.0–7.0]
Walking speed: m/s 0.71 (0.34) 0.87 (0.44) 0.81 (0.42)
COP sway path: mm 625 (317) 580 (357) 599 (333)
DHI score 44.0 (15.1) 47.8 (22.1) 46.2 (17.7)
All values are presented as mean (standard deviation), unless indicated otherwise.
All 𝑃 values are >0.2.
of accidental falls (i.e., an unexpected contact of any part of
the body on the ground).
2.4. Statistical Analysis. Baseline differences between respon-
ders and nonresponders were tested by the Mann-Whitney
U or the Fisher Exact tests for continuous and categorical
variables, respectively.
A repeated measures analysis of variance (ANOVA) was
carried out to estimate the main effects of time (within-
subject factor) and time by group (responders versus nonre-
sponders, between-subject factor), with log-normalized COP
path values at different time-points as dependent variable.
Data on COP path were log-transformed since they were
not normally distributed. Mauchly’s test indicated that the
sphericity assumption was satisfied; therefore correction for
degrees of freedom was not necessary.
Changes over time in DHI and its subscales were investi-
gated by the Wilcoxon Rank Sum test.
The incidence rate ratio of falls per person per month was
also investigated for responders and nonresponders.
𝑃 values less than 0.05 in either direction were considered
as statistically significant. Analyses were carried out by using
the Statistical Package for Social Sciences, version 16.0 (IBM
SPSS, Chicago, IL, USA).
3. Results
Demographic and clinical characteristics of study sample at
study entry are shown in Table 1. After the 2-week run-in
period, 8 (40%) patients resulted as responders and 12 (60%)
as nonresponders. The mean walking speed improvement,
assessed with 25-FWT, was 33% and 8% in responders and
nonresponders, respectively (𝑃 = 0.001). No adverse events,
other than accidental falls, occurred during the 14-week study
period. None of the reported falls resulted in a major injury
or fracture. No seizures were reported.
We did not find any significant main effect of time on
postural sway (𝐹[4,15] = 1.591, 𝑃 = 0.231), while a significant
time by group interaction was observed (𝐹[4,15] = 3.959, 𝑃 =
0.027), indicating a reduced postural sway in the treatment
responder group.
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Figure 2: Mean absolute difference (±standard error, SE) in COP
sway displacement (mm) from screening (WK−2) value. Negative
values refer to improved standing balance. SE: standard error. ∗PR
dalfampridine taken only by treatment responders.
Simple contrast analyses revealed a significant improve-
ment in postural sway of responders atWK+2 (𝐹[1,18] = 9.346,
𝑃 = 0.008; mean change from visit WK−4: −10%) andWK+6
(𝐹[1,18] = 5.193, 𝑃 = 0.037; mean change from visit WK−4:
−7%), but not at the end of study (𝐹[1,18] = 2.855, 𝑃 =
0.234; mean change from visit WK−4: −4%) compared to
pretreatment values. Postural sway of nonresponders tended
to worsen, with a 7% increase of postural sway at study
termination (see Figure 2).
There were no significant changes fromWK−4 toWK+10
visits in DHI total score neither in treatment responders (𝑃 =
0.121) nor in nonresponders (𝑃 = 0.482). Similar findings
were found even considering DHI subscales (functional,
physical, and emotional), with nonsignificant 𝑃 values from
0.293 to 0.150 and from 0.959 to 0.191 in treatment responders
and nonresponders, respectively.
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Similar rates of accidental falls per person permonthwere
observed in treatment responders (0.875 fromWK−4 to WK
0 visits; 0.625 fromWK+2 toWK+6 visits; 0.375 fromWK+6
to WK+10 visits) and nonresponders (0.833 from WK–4 to
WK 0 visits; 0.667 from WK+2 to WK+6 visits; 0.375 from
WK+6 to WK+10 visits) (𝑃 = 0.82).
4. Discussion
The main finding of this study is that response to PR
dalfampridine was associated with significant, short-term,
improvement in standing balance (detected at static postur-
ography).
Moreover, there was a relevant and sustained dissociation
between responders and nonresponders in terms of postural
sway differences with respect to pretreatment performance,
even though treatment responders returned toward baseline
values. These latter findings might be explained by the
progressive nature of the disease.However, we cannot exclude
the hypothesis of a “boost” effect of PR dalfampridine,
which tends to decrease over time. Consistently with this
hypothesis, a recent postmarketing experience has reported
significant improvement in walking speed only after two
weeks from treatment start, not confirmed on a longer-
term period [19]. Conversely, the beneficial effect of PR dal-
fampridine on other clinical parameters, such as maximum
walking distance, and patient-reported outcome of motor
and cognitive fatigue, was maintained up to 12 months from
treatment start [19].
The significant improvement in standing balance of treat-
ment responders might be explained by at least three distinct
(and perhaps mutually reinforcing) mechanisms.
First, by quickly restoring nerve conduction, probably
driven by an enhanced excitatory synaptic transmission
[5, 20], PR dalfampridine might be able to improve the
integration of afferent signals into the central nervous system.
Central integration deficit, due to thewidespread and variable
distribution of demyelination and axonal loss, can be consid-
ered as a major contributor of balance deficit in MS [21].
Second, PR dalfampridine might improve anticipatory
postural adjustments by increasing lower extremity strength.
Lesser directional-specific and smaller magnitudes of antici-
patory muscle activation were in fact reported even in mildly
disabled patients with MS [22].
Third, PR dalfampridine might enhance the inhibitory
drive and precision of pacemaking of cerebellar Purkinje
cells, as also supported by animal studies on its analogue
4-aminopyridine (4-AP) [23]. Some studies showed the
ability of 4-AP in ameliorating not only specific cerebellar
dysfunctions, such as type-2 episodic ataxia and downbeat
nystagmus [24], but also upper limb tremor and dysarthria
due to MS [25, 26].
The role of cerebellum damage in determining standing
balance impairment has been also recently emphasized in
nonconventional magnetic resonance imaging studies [27],
thus reinforcing this latter hypothesis.
Among the PR dalfampridine-related adverse events,
randomized clinical trials described an increased incidence
of dizziness and balance disorders, especially in the first 4–
8 weeks of treatment. Nevertheless, a similar incidence of
accidental falls in active and placebo arms [8, 9] has been
reported. Consistently with clinical trials, the incidence of
fallers was similar in responder and nonresponder group
in our experience, suggesting that response to PR dalfam-
pridine could not be considered a risk factor for accidental
falls. Moreover, patients’ self-perception of disability due to
balance problems, as assessed by DHI and its subscales,
was not affected by treatment response to PR dalfampridine.
However, the interpretation of these latter findings, especially
that one about the risk of accidental falls, must be cautious,
given the small population enrolled in our study.
The major limits of our study mainly encompass its
observational, nonrandomized design, the lack of a placebo-
controlled group, and the small sample size. However, the
use of computer-basedmeasures of standing balance, that are
accurate and reliable in MS setting [28], provided data more
objective than clinical scales.
Findings from our study require to be confirmed by
further prospective studies on larger sample sizes and even
on a long-term period.
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